The DOI matches its Crossref record; 244 of the 244 references it cites were found in a registry or an index.
Anakinra Therapy for Non-cancer Inflammatory Diseases
Open accessAbstract
Interleukin-1 (IL-1) is the prototypic inflammatory cytokine: two distinct ligands (IL-1α and IL-1β) bind the IL-1 type 1 receptor (IL-1R1) and induce a myriad of secondary inflammatory mediators, including prostaglandins, cytokines and chemokines. IL-1α is constitutively present in endothelial and epithelial cells whereas IL-1β is inducible in myeloid cells and released following cleavage by caspase 1. Over the past 30 years, IL-1-mediated inflammation has been established in a broad spectrum of diseases, ranging from rare autoinflammatory diseases to common conditions such as gout and rheumatoid arthritis, type 2 diabetes, atherosclerosis, and acute myocardial infarction. Blocking IL 1 entered the clinical arena with anakinra, the recombinant form of the naturally occurring IL 1 Receptor antagonist (IL 1Ra); IL 1Ra prevents the binding of IL 1α as well as IL 1β to IL 1R1. Quenching IL 1-mediated inflammation prevents the detrimental consequences of tissue damage and organ dysfunction. Although anakinra is presently approved for the treatment of rheumatoid arthritis and cryopyrin-associated periodic syndromes, off-label use of anakinra far exceeds its approved indications. Dosing of 100 mg of anakinra subcutaneously provides clinically evident benefits within days and for some diseases, anakinra has been used daily for over 12 years. Compared to other biologics, anakinra has an unparalleled record of safety and opportunistic infections, particularly Mycobacterium tuberculosis are rare, even in populations at risk for reactivation of latent infections. Because of this excellent safety profile and relative short duration of action, anakinra can also be used as a diagnostic tool for undefined diseases mediated by IL 1. Although anakinra is presently in clinical trials to treat cancer, this review focuses on anakinra treatment of acute as well as chronic inflammatory diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–244 of 244
Kuemmerle-Deschner, J. B., Lohse, P., Koetter, I., Dannecker, G. E., Reess, F., Ummenhofer, K., Koch, S., Tzaribachev, N., Bialkowski, A., & Benseler, S. M. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3526 · Cited by 61
IL-1 Inhibition May Have an Important Role in Treating Refractory Kawasaki Disease
Dusser, P., & Koné‐Paut, I. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00163 · Cited by 61
Hsieh, C., Chen, Y., Lin, C., Tang, K., Chen, H., Hung, W., Lai, K., & Chen, D. (2017) · The Journal of Rheumatology · doi:10.3899/jrheum.161354 · Cited by 61
An Overview of Interleukin-1 Receptor Antagonist, Anakinra, in the Treatment of Cutaneous Diseases
Pazyar, N., Feily, A., & Yaghoobi, R. (2012) · Current Clinical Pharmacology · doi:10.2174/157488412803305821 · Cited by 60
Settas, L., Tsimirikas, G., Vosvotekas, G., Triantafyllidou, E., & Nicolaides, P. (2007) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0b013e31812e00a1 · Cited by 57
Cytokine profiles in children with primary Epstein–Barr virus infection
Wada, T., Muraoka, M., Yokoyama, T., Toma, T., Kanegane, H., & Yachie, A. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24480 · Cited by 57
Hayashi, M., Jin, Y., Yorgov, D., Santorico, S. A., Hagman, J. R., Ferrara, T. M., Jones, K. L., Cavalli, G., Dinarello, C. A., & Spritz, R. A. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525001113 · Cited by 57
Self-citationTreating Pulmonary Silicosis by Blocking Interleukin 1
Cavalli, G., Fallanca, F., Dinarello, C. A., & Dagna, L. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201412-2150le · Cited by 56
Self-citationPillinger, M. H. (2006) · Yearbook of Medicine · doi:10.1016/s0084-3873(08)70352-3 · Cited by 55
Cantarini, L., Lucherini, O. M., Cimaz, R., & Galeazzi, M. (2010) · PubMed · Cited by 55
Ballak, D. B., Li, S., Cavalli, G., Stahl, J. L., Tengesdal, I. W., van Diepen, J. A., Klück, V., Swartzwelter, B. J., Azam, T., Tack, C. J., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.003698 · Cited by 55
Self-citationCytophagic histiocytic panniculitis and hemophagocytic lymphohistiocytosis: an overview
Aronson, I. K., & Worobec, S. M. (2010) · Dermatologic Therapy · doi:10.1111/j.1529-8019.2010.01339.x · Cited by 54
Ogilvie, A. C., Hack, C. E., Wagstaff, J., van Mierlo, G. J., Erenberg, A. J., Thomsen, L. L., Hoekman, K., & Rankin, E. M. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.1.389 · Cited by 54
IL-1RA Agonist (Anakinra) in the Treatment of Multifocal Castleman Disease: Case Report
Galeotti, C., Tran, T., Franchi-Abella, S., Fabre, M., Pariente, D., & Koné-Paut, I. (2008) · Journal of pediatric hematology/oncology · doi:10.1097/mph.0b013e31818ab31f · Cited by 52
Oncogene-Induced Senescence as a New Mechanism of Disease: The Paradigm of Erdheim–Chester Disease
Cavalli, G., Biavasco, R., Borgiani, B., & Dagna, L. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00281 · Cited by 50
Self-citationHyper-IgD syndrome or mevalonate kinase deficiency
Stoffels, M., & Simon, A. (2011) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e328349c3b1 · Cited by 48
Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheim–Chester Disease
Tomelleri, A., Cavalli, G., Luca, G. D. D., Campochiaro, C., D’Aliberti, T., Tresoldi, M., & Dagna, L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01233 · Cited by 46
Self-citationRaffeiner, B., Botsios, C., Dinarello, C. A., Ometto, F., Punzi, L., & Ramonda, R. (2010) · Joint Bone Spine · doi:10.1016/j.jbspin.2010.09.014 · Cited by 45
Self-citationTreatment of Dilated Cardiomyopathy With Interleukin-1 Inhibition
De Luca, G., Campochiaro, C., Dinarello, C. A., Dagna, L., & Cavalli, G. (2018) · Annals of Internal Medicine · doi:10.7326/l18-0315 · Cited by 42
Self-citationTocilizumab in patients with multisystem Erdheim–Chester disease
Berti, A., Cavalli, G., Guglielmi, B., Biavasco, R., Campochiaro, C., Tomelleri, A., Nicoletti, R., Panzacchi, A., Ferrarini, M., & Dagna, L. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1318237 · Cited by 42
Self-citationLipsker, D. M., Perrigouard, C., Foubert, A., & Cribier, B. J. (2010) · Dermatology · doi:10.1159/000280436 · Cited by 39
Interleukin-1α, Interleukin-1β, and Interleukin-1Ra Polymorphisms in Febrile Seizures
Haspolat, Ş., Baysal, Y., Duman, Ö., Coşkun, M., Tosun, Ö., & Yein, O. (2005) · Journal of Child Neurology · doi:10.1177/08830738050200070401 · Cited by 38
Lopalco, G., Rigante, D., Giannini, M., Galeazzi, M., Lapadula, G., Iannone, F., & Cantarini, L. (2016) · PubMed · Cited by 38
Imazio, M. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.965150 · Cited by 37
Febrile Seizures: Interleukin 1β and Interleukin-1 Receptor Antagonist Polymorphisms
Serdaroğlu, G., Alpman, A., Tosun, A. F., Pehlıvan, S., Özkınay, F., Tekgül, H., & Gökben, S. (2009) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2008.10.004 · Cited by 37
Scott, I. C., Hajela, V., Hawkins, P. N., & Lachmann, H. J. (2011) · Journal of Cardiology Cases · doi:10.1016/j.jccase.2011.07.003 · Cited by 34
Hennig, S., Bayegan, K., Uffmann, M., Thalhammer, F., & Winkler, S. (2010) · Rheumatology International · doi:10.1007/s00296-010-1429-y · Cited by 33
Punzi, L., Gava, A., Galozzi, P., & Sfriso, P. (2011) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2011.10.017 · Cited by 31
Macrophage Activation Syndrome Secondary to Human Monocytic Ehrlichiosis
Kumar, N., Goyal, J., Goel, A., Shakoory, B., & Chatham, W. W. (2013) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-013-0299-3 · Cited by 29
The fibrogenic chemokine CCL18 is associated with disease severity in Erdheim-Chester disease
Pacini, G., Cavalli, G., Tomelleri, A., Luca, G. D. D., Pacini, G., Ferrarini, M., Doglioni, C., & Dagna, L. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1440929 · Cited by 23
Self-citationBotsios, C., Sfriso, P., Furlan, A., Ostuni, P., Biscaro, M., Fiocco, U., TODESCO, S., & Punzi, L. (2011) · Reumatismo · doi:10.4081/reumatismo.2007.32 · Cited by 22
Honda, K., Ohga, S., Takada, H., Nomura, A., Ohshima, K., Kinukawa, N., Mizuno, Y., & Hara, T. (2000) · PubMed · Cited by 21
Anakinra for the inflammatory complications of chronic granulomatous disease.
van de Veerdonk, F. L., Netea, M. G., Dinarello, C. A., & van der Meer, J. W. M. (2011) · PubMed · Cited by 21
Self-citationKlein, A., & Horneff, G. (2010) · Klinische Pädiatrie · doi:10.1055/s-0029-1239527 · Cited by 20
Chiapparini, L., Cavalli, G., Langella, T., Venerando, A., Luca, G. D. D., Raspante, S., Marotta, G., Pollo, B., Lauria, G., Cangi, M. G., et al. (2017) · Journal of Neurology · doi:10.1007/s00415-017-8692-8 · Cited by 19
Self-citationChoi, A., Moles, V., Fuisz, A., & Weissman, G. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.12.151 · Cited by 17
Interleukin-18 does not modulate the acute-phase response
Stuyt, R. J. L., Netea, M. G., Verschueren, I., Dinarello, C. A., Kullberg, B. J., & van der Meer, J. W. M. (2005) · Journal of Endotoxin Research · doi:10.1177/09680519050110020301 · Cited by 17
Self-citationLasting remission of a Muckle–Wells syndrome with CIAS-1 mutation using half-dose anakinra
Gerard, S., Goff, B. L., Maugars, Y., Berthelot, J., & Malard, O. (2007) · Joint Bone Spine · doi:10.1016/j.jbspin.2007.01.032 · Cited by 17
Anakinra for myocarditis in juvenile idiopathic arthritis.
Movva, R., Brown, S. B., Morris, D. L., & Figueredo, V. M. (2013) · PubMed · Cited by 14
Plasma Chromogranin A as a marker of cardiovascular involvement in Erdheim–Chester disease
Ferrero, E., Corti, A., Haroche, J., Belloni, D., Colombo, B., Berti, A., Cavalli, G., Campochiaro, C., Villa, A., Aubart, F. C., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1181244 · Cited by 14
Self-citationAdvances in potential targeted therapies for Erdheim-Chester disease
Cavalli, G., Luca, G. D. D., & Dagna, L. (2017) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2017.1285226 · Cited by 14
Self-citationMuckle-Wells syndrome: a treatable cause of congenital sensorineural hearing loss.
Stew, B. T., Fishpool, S. J. C., Owens, D., & Quine, S. M. (2013) · PubMed · Cited by 13
Muckle-Wells treatment with anakinra
Eungdamrong, J., Boyd, K. P., Meehan, S. A., & Latkowski, J.-A. M. (2013) · Dermatology Online Journal · doi:10.5070/d31912020720 · Cited by 10
Diagnosing Erdheim–Chester disease
Cavalli, G., Berti, A., Campochiaro, C., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203685 · Cited by 10
Self-citation
Cited by
Harnessing cytokines and chemokines for cancer therapy
Propper, D. J., & Balkwill, F. R. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00588-9 · Cited by 989
Endometriosis: Etiology, pathobiology, and therapeutic prospects
Saunders, P. T. K., & Horne, A. W. (2021) · Cell · doi:10.1016/j.cell.2021.04.041 · Cited by 961
Bonnardel, J., T’Jonck, W., Gaublomme, D., Browaeys, R., Scott, C. L., Martens, L., Vanneste, B., De Prijck, S., Nedospasov, S. A., Kremer, A., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.08.017 · Cited by 631
Moving towards personalized treatments of immune-related adverse events
Esfahani, K., Elkrief, A., Calabrese, C., Lapointe, R., Hudson, M., Routy, B., Miller, W. H., & Calabrese, L. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0352-8 · Cited by 351
Gressler, M., Heddergott, C., N'Go, I. C., Renga, G., Oikonomou, V., Moretti, S., Coddeville, B., Gaifem, J., Silvestre, R., Romani, L., et al. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00365 · Cited by 27
Metadata
- Authors
- Cavalli, G., & Dinarello, C. A.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2018-11-06
- Volume
- 9
- Pages
- 1157-1157
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2899747393
- Cited by
- 292
- References
- 244
- FWCI
- 10.36
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.